SEP 13, 2018 12:00 PM PDT

Outer Membrane Remodeling of Attenuated Salmonella to Create a Mucosal Vaccine Against Acinetobacter Baumannii

Speaker

Abstract

While rapid identification of pathogens, novel therapeutic interventions, and passive immunization have critical roles in disease control, none can substitute for pre-existing protective immunity. Mucosally delivered bacterial live vector vaccines represent a practical and effective strategy for immunization.  In live vector vaccines, genes that encode protective antigens of unrelated pathogens are expressed in an attenuated vaccine strain and delivered mucosally to generate relevant local and systemic immune responses. We hypothesize that by appropriate manipulation of novel Salmonella enterica serovar Typhi live vector platform technologies, we can construct a mucosally administered bivalent vaccine against potentially lethal infections caused by Acinetobacter baumannii.  Our unique research strategy is designed to remodel the outer membrane of an attenuated S. Typhi-based live vector vaccine into an antigen presentation platform in which protective outer membrane antigens from A. baumannii are mucosally delivered to immune inductive sites via a novel inducible outer membrane vesicle delivery system. Mucosal delivery of recombinant outer membrane vesicles (rOMVs) via live vector vaccines offers significant advantages over conventional acellular OMV-based vaccination strategies including: 1] sustained in vivo delivery to mucosal inductive sites, and 2] delivery of rOMVs enriched in properly folded protective antigens. To enhance delivery of these protective antigens to immune effector cells, thereby improving the protective efficacy of this mucosal vaccine, we enhance delivery of rOMVs through inducible over-expression of the hypervesiculating protein PagL. If successful, our novel and highly innovative approach could result in a mucosal live carrier vaccine, effective against potentially lethal systemic and pulmonary infections with A. baumannii, which could prove highly valuable in both civilian and military settings.

Learning Objectives: 

1. What is a carrier vaccine?    
2. How can carrier vaccines be used to combat the antibiotic resistance crisis in public health?


Show Resources
You May Also Like
AUG 24, 2022 7:00 AM PDT
AUG 24, 2022 7:00 AM PDT
Date: August 24, 2022 Time: 7:00am (PDT), 10:00pm (EDT), 4:00pm (CEST) Light field microscopy was first introduced in 2006, and allows users to capture the 4D light field within the microsco...
MAY 17, 2022 9:00 AM PDT
MAY 17, 2022 9:00 AM PDT
Date: May 17, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 8:00pm (CEST) Gene therapeutics have great potential to treat many severe diseases in an unprecedented, targeted manner. The biopharmace...
JUN 28, 2022 7:00 AM PDT
JUN 28, 2022 7:00 AM PDT
Date: June 28, 2022 Time: 3:00pm (BST), 4:00pm (CET), 9:00am (CST), 7am (PST) Light-sheet microscopy is an extremely versatile imaging technique with a vast range of implementations that are...
SEP 13, 2022 8:00 AM PDT
SEP 13, 2022 8:00 AM PDT
Date: September 13, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Preparedness against pandemic diseases demands rapid-response vaccine technology and ready-to-use analytical methods...
JUN 29, 2022 8:00 AM PDT
JUN 29, 2022 8:00 AM PDT
Date: June 29, 2022 Time: 8:00am (PST), 11:00am (EST), 5:00pm (CEST) As of May 2022, there have been more than 500 million confirmed cases of COVID-19, including numerous variants. Additiona...
JUN 01, 2022 9:00 AM PDT
JUN 01, 2022 9:00 AM PDT
Date: June 01, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 6:00pm (CEST) The manufacturing process for cell and gene therapies is complex and can contain process-related impurities from multiple...
SEP 13, 2018 12:00 PM PDT

Outer Membrane Remodeling of Attenuated Salmonella to Create a Mucosal Vaccine Against Acinetobacter Baumannii



Show Resources
Loading Comments...
Show Resources